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Abstract
Introduction Drug use in pregnancy is very common but
may cause harm to the fetus. The teratogenic effect of a
drug is partly dependent on the drug level in the fetal cir-
culation, which is associated with the transport across the
placenta. Many drugs are substrates of P-glycoprotein (P-
gp), an efflux transporter that acts as a protective barrier for
the fetus. We aim to identify whether drug interactions
associated with P-gp promote any changes in fetal drug
exposure, as measured by the risk of having children with
congenital anomalies.
Methods In this study, cases (N = 4634) were mothers of
children with congenital anomalies registered in the
EUROCAT Northern Netherlands registry, and the refer-
ence population were mothers of children (N = 25,126)
from a drug prescription database (IADB.nl).
Results Drugs that are associated with P-gp transport
were commonly used in pregnancy in cases (10 %) and
population (12 %). Several drug classes, which are sub-
strates for P-gp, were shown to have a higher user rate in
mothers of cases with specific anomalies. The use of this
subset of drugs in combination with other P-gp substrates
increased the risk for specific anomalies (odds ratio [OR]
4.17, 95 % CI 1.75–9.91), and the addition of inhibitors
further increased the risk (OR 13.03, 95 % CI 3.37–50.42).
The same pattern of risk increment was observed when the
drugs were analyzed separately according to substrate
specificity.
Conclusions The use of drugs associated with P-gp
transport was common during pregnancy. For several drug
classes associated with specific anomalies, P-gp-mediated
drug interactions are associated with an increased risk for
those specific anomalies.
Key Points
Several drugs used in the first trimester of pregnancy
are transported by P-glycoprotein (P-gp), an efflux
transporter expressed in the placenta.
Some of these drugs were shown to have associations
with specific types of anomalies. Drug interactions
mediated by P-gp increase the risk of specific
anomalies of these drugs compared with their use
alone.
The pattern of risk increment following drug
interactions suggests the role of P-gp in limiting fetal
drug exposure.
Electronic supplementary material The online version of this
article (doi:10.1007/s40264-015-0299-3) contains supplementary
material, which is available to authorized users.
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1 Introduction
Drug use in pregnancy is inevitable in some conditions,
particularly in chronic diseases such as diabetes, depression
and epilepsy. Drugs are also often prescribed to alleviate
the symptoms associated with pregnancy or to fight in-
fections [1]. In fact, between 27 and 93 % of pregnant
women in several developed countries were prescribed
drugs, excluding vitamins and minerals, during pregnancy
[2]. Moreover, the prescription rate during the first trime-
ster is approximately 40 %, and nearly 3 % of the pregnant
women were prescribed drugs suspected to be teratogenic
to the fetus [1, 3].
The risk of drug teratogenicity is dependent on the de-
gree of fetal exposure, which is regulated partly by the
transporter proteins in the placenta [4]. One of the most
abundant transporter proteins is P-glycoprotein (P-gp), an
efflux transporter expressed in the maternal-facing surface
of the placental tissue [5, 6]. P-gp acts as a barrier to
preventing some potentially harmful drugs from entering
the fetal circulation, and its function can be modulated by
inhibitors and inducers [5, 7]. Many drugs are known to be
substrates of P-gp, some of which may also inhibit or in-
duce this transporter. The use of P-gp inhibitors or inducers
in combination with a substrate, referred to as ‘P-gp-me-
diated drug interactions’, may affect the P-gp barrier
function in the placenta and subsequently fetal exposure to
this substrate. For substrates that are teratogenic, the
changes in transport and thereby of fetal exposure may be
reflected in a changed risk of fetal congenital anomalies.
Despite the importance of drug interactions in the placenta
for fetal outcome, far too little attention has been given to
this issue.
P-gp-mediated drug interactions have been previously
explored in in vitro and in vivo studies [8, 9]. P-gp in-
hibitors increase the placental transfer of P-gp substrates in
placental samples of late pregnancy [10]; however, the
level of P-gp expression changes during pregnancy and the
effect on fetal drug exposure during the early stage of
pregnancy is not really known. There is still no established
method to pursue this, particularly because of the difficulty
in obtaining placental samples in early pregnancy.
The aim of this study was to explore the role of P-gp on
fetal drug exposure in the first trimester of pregnancy.
Applying a case-reference study design, we used the out-
come of congenital anomalies as a proxy for fetal drug
exposure. The first objective was to describe the pattern of
use of drugs associated with P-gp transport during the first
trimester of pregnancy, while the second objective was to
determine the effect of P-gp-mediated drug interactions on
the risk of congenital anomalies in exposed children.
2 Methods
2.1 Case Selection
Cases were selected among the mothers of children regis-
tered by EUROCAT Northern Netherlands (NNL), a
population-based registry covering the northern provinces
of The Netherlands (Groningen, Friesland and Drenthe).
The registry includes fetuses or children, up to the age of
10 years, with congenital anomalies diagnosed before or
after birth. All mothers of the children in this study gave
consent to register their child in EUROCAT. EUROCAT
records detailed information on the sociodemographic and
lifestyle characteristics of the mothers, obtained through
questionnaires. With the consent of the mothers, the in-
formation on drug use from 3 months before conception
until delivery was collected from the pharmacy records and
was later verified by telephone interviews. Among eligible
children born in the study period (1997–2013), 81.6 % of
parents gave consent to register their child in EUROCAT,
and 80.2 % returned the questionnaire and gave consent to
retrieve their pharmacy data (personal communication).
The actual use of both prescribed drugs, as well as over-
the-counter (OTC) drugs, was completely registered, in-
cluding the prescription status of any OTCs used (whether
they were prescribed or not). Other details on drug use
included, among others, the Anatomical Therapeutic Che-
mical (ATC) codes and the period of use during pregnancy.
The congenital anomalies were classified based on the
EUROCAT Subgroup of Congenital Anomalies [11] and the
International Classification of Diseases (ICD) coding sys-
tem, ninth revision (ICD9) until 2001 and tenth revision
(ICD10) from 2002 onwards. Only major anomalies were
included in this study. The EUROCAT Subgroups of Con-
genital Anomalies (ICD9, ICD10) were anomalies of the
nervous system (740–742, Q00–Q07), eye, ear, face and
neck (743–744, Q10–Q18), heart (745, 746, 7470–7474,
Q20–Q26), respiratory (748, Q30–Q34), orofacial clefts
(7490–7492, Q35–Q37), digestive system (750–751, 7566,
Q38–Q45, Q790), urinary (753, 75,672, 75,261, Q60–Q64,
Q794), and genital (7520–7524, 75,260, 75,262, 7527–7529,
Q50–Q52, Q54–Q56). Two subgroups of anomalies were
classified according to the ICD10, i.e. (ICD9, ICD10)
anomalies of the musculoskeletal system (754, 7566–7567,
Q65–Q66, Q790–Q795) and limb (755, Q69–Q74).
A total of 6934 children with congenital anomalies were
born between 1 January 1997 and 31 December 2013.
Overall, 885 children with genetic and chromosomal ab-
normalities were excluded because these anomalies were
not likely to be related to drug use. We selected 5268 of the
cases in which mothers had a history of drug use during
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pregnancy to match the reference population from a pre-
scription database. Mothers with a previous history of
children with anomalies were excluded in order to avoid
selection bias in drug selection and prescribing, which led
to recruitment of 4634 cases.
2.2 Reference Population Sampling
Reference data were obtained from the IADB.nl, a longitu-
dinal, population-based prescription database in The
Netherlands. The data were collected from 55 community
pharmacies, including Groningen, Friesland and Drenthe,
and covered an estimated population of 600,000 people. The
prescription rates in this population have been found to be
representative for the whole population in The Netherlands
in comparison with data from insurance companies
throughout the whole country [12]. Pharmacies periodically
update the data of all delivered drugs for all patients, as
prescribed by both general practitioners and specialists in the
outpatient clinics. Data include the name of the prescribed
drug, date of dispensing, quantity dispensed, dose regimen,
prescribing physician and ATC codes [12].
A pregnancy database, Pregnancy IADB, was obtained
from a large mother–child subset extracted from IADB.nl.
All live-born children born between 1997 and 2013 were
selected from this database. For each child, the female
person aged 15–50 years older than the child and registered
to the same address code is considered to be the mother. If
there is another female person in that age range and with
the same address code, the child will be excluded. Ap-
proximately 65 % of children in the main IADB.nl data-
base are linked to their mother, and validation of the
identified mothers showed 99 % accuracy [13].
The gestational period was determined from the theo-
retical conception date by subtracting the date of birth of
the children with 273 days (gestational period of
9 months). Since the gestation period for twin and triplet
pregnancies is likely to be shorter than singleton preg-
nancies, twin and triplet pregnancies were excluded. These
pregnancies were identified based on the number of chil-
dren with the same date of birth who were linked to the
same mother. If more than one child was linked, the mother
was excluded.
All registered pregnancies in the Pregnancy IADB, re-
gardless of the number of pregnancies per mother, were the
source population (N = 38,129). We then selected only the
first registered pregnancy for each mother as the reference
population (N = 25,126). The first known pregnancy for
each mother was selected to overcome misclassification
bias in maternal drug use since drug selection may be in-
fluenced by the previous pregnancy outcome. Ethical ap-
proval was not necessary for cases and population sampling
since only anonymous data were used.
2.3 Exposure Variable
The user rates of drugs associated with P-gp transport
during pregnancy were described in the source population
to give a general overview of the prevalence at the
population level. The P-gp drugs were identified through a
literature review and classified according to substrate affi-
nity, consisting of P-gp substrate, substrate/inhibitor, sub-
strate/inducer, inhibitor, inducer, inhibitor/inducer and
substrate/inhibitor/ inducer [5, 14–16]. This classification
was determined by the results from in vivo studies and if
not available, in vitro studies. More details on the list of all
identified drugs are available in electronic supplementary
Table 1. Drugs that are substrates/inducers are substrates
when used alone but act as inducers to P-gp in the presence
of another substrate. The same applies for substrates/in-
hibitors, which may inhibit the transport of another P-gp
substrate when both are used concurrently. Inhibitors/in-
ducers and substrates/inhibitors/inducers may become ei-
ther one of these classes depending on substrate selectivity
to P-gp in comparison with the other interacting drug.
The user rates include OTC drugs. The Dutch OTC drug list
was obtained from the Medicines Evaluation Board of The
Netherlands.Theperiodof exposurewas restricted to theperiod
of organogenesis, i.e. the first trimester. Some drugs that are
dispensed before the conception date may also be continually
used during the first trimester, therefore we also included the
preconception period. Children were considered to be exposed
to the drugs if the periodof the drugs dispensed/usedwaswithin
90 days before conception and the first 90 days of pregnancy.
To determine the effect of P-gp-mediated drug interactions
on the risk of congenital anomalies, only drugs that showed
associations with teratogenicity were selected. To find po-
tential teratogenic drugs, we first grouped the drugs into drug
classes according to their pharmacological action. Second, we
calculated the user rates of these drug classes for all EURO-
CAT Subgroups of Congenital Anomalies. Drug classes with
significantly higher user rates in specific subgroups of con-
genital anomalies were selected as ‘drugs with associations’.
Information on the use of OTCs is not complete in the
Pregnancy IADB; therefore, for a better comparison with
cases, the use of OTC drugs was disregarded in this ana-
lysis. Throughout the study period, four drugs underwent
changes in prescription regulation in The Netherlands
(OTC to prescription drug, and vice versa), i.e. ranitidine,
domperidone, omeprazole and pantoprazole. We included
the exposure of these drugs among the case group, only
when they were prescribed, so that the exposure status was
comparable to the reference population.
Exposure was defined as mothers presented with P-gp-
mediated drug interaction patterns, which included the
combination of drugs transported by P-gp with another
substrate and/or inducer and/or inhibitor.
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2.4 Statistical Analysis
The analysis strategy for drug interaction patterns was
conducted based on a priori hypothesis in which the dis-
tribution of types of medication used would differ between
cases and the reference population, with an increased use in
cases indicating a possible interaction. We also stratified
the drug interaction analysis into substrate specificity
(substrates, substrates/inhibitors) to observe whether the
risk on anomalies was different for each group of drugs.
The Chi-square test was used in the comparison between
the number of users in cases of specific anomalies and
other anomalies. The number of cases of specific anomalies
was then compared with the number of the reference
population presented with the same pattern of P-gp-medi-
ated drug interactions by calculating the odds ratio (OR)
and 95 % confidence interval (CI). An OR of more than 1
indicated an increased risk for congenital anomalies with
certain interaction patterns. The results were considered as
statistically significant at p\ 0.05. Since some drugs are
classified as ‘P-gp substrate’ and some as ‘P-gp substrate/
inhibitor’, the analysis was conducted separately for each
group. Analyses were performed using PASW Statistics,
version 22 (IBM Corporation, Armonk, NY, USA).
3 Results
Characteristics of the children born to case mothers are
presented in Table 1. The majority of children were live
born, and the most common types of anomalies were the
heart and musculoskeletal anomalies, which were each
present in more than 20 % of the children.
Maternal age at delivery was comparable between cases,
source and reference populations, i.e. 30.3 years for case
mothers, 30.0 years for mothers from the source population
and 29.4 years for mothers from the reference population.
A lower number of children were born in the last 5 years of
the study period (2009–2013) in the source population
(18 %) and reference population (15 %) compared with
cases (22 %) because children were only registered in the
IADB.nl once they received any prescription drug.
3.1 User Rates of Drugs Associated with P-
Glycoprotein (P-gp) During Pregnancy
The use of drugs associated with P-gp transport is fairly
common during pregnancy. Of 105 P-gp substrates iden-
tified in the literature, including OTC drugs, 44 were used
by at least one case mother, while 66 were prescribed to at
least one mother in the source population. The list of drugs
and number of users among the cases and the reference
population is available in the electronic supplementary
Table 1. Furthermore, one or more of these drugs were
used by 17.7 % (n = 820) of case mothers and 14.5 %
(n = 5543) of mothers in the source population, suggesting
that drugs associated with P-gp transport are widely used,
even in pregnancy. The Pregnancy IADB also records the
OTCs but only when the drugs are prescribed by physi-
cians; therefore, the number of users in the source
population is likely to be underestimated.
Among case mothers, 10.4 % (n = 481) had used at
least one drug associated with P-gp transport, and 12.0 %
(n = 3022) of mothers in the reference population were
prescribed these drugs. The user rates and prescription rates
of these drugs, according to substrate specificity, are shown
in Fig. 1. Doxycycline, a P-gp substrate, was the most
commonly used or prescribed drug (case mothers, n = 102
[2.2 %]; reference mothers, n = 595 [2.4 %]), followed by
omeprazole, a P-gp substrate/inhibitor (case mothers,
n = 41 [0.9 %]; reference mothers, n = 294 [1.2 %]). For
drug groups indicated for chronic diseases, the user rate of
selective serotonin reuptake inhibitors (SSRIs) was the
highest [case mothers, n = 86 (1.9 %); reference mothers,
n = 607 (2.4 %)] compared with other antidepressants,
antipsychotics and antiepileptics.
In the selection of drugs with associations, most OTCs
were excluded, as explained in the Methods section.
Among cases, 13 drugs were identified that were used in a
higher percentage in cases with specific anomalies







Live birth 4361 94.1
Termination of pregnancy 184 4.0
Stillbirth 58 1.3




Digestive system 594 12.8
Urinary 507 10.9
Orofacial clefts 436 9.4
Genital 406 8.8
Nervous system 347 7.5
Limb 342 7.4
Eye, ear, face and neck 152 3.3
Respiratory 84 1.8
a Percentages do not add up to 100 as cases with multiple anomalies
were counted more than once
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compared with cases with other anomalies (Table 2).
Cimetidine and ranitidine (H2-receptor antagonists) were
shown to have an association with heart anomalies
(p = 0.037), omeprazole and pantoprazole (proton pump
inhibitors [PPIs]) with genital anomalies (p = 0.046),
morphine with respiratory anomalies (p = 0.018), and
antipsychotics (haloperidol, quetiapine and risperidone)
with musculoskeletal anomalies (p = 0.018). Drugs that
were found to have associations with specific anomalies
were grouped as ‘drugs with associations’ and were used in
the risk estimation analysis for P-gp-mediated drug inter-
actions in congenital anomalies. The association between
SSRIs (paroxetine, sertraline, fluoxetine, fluvoxamine, ci-
talopram) and nervous system anomalies nearly reached
statistical significance (p = 0. 054), but due to previous
warnings of teratogenicity, this drug class was also clas-
sified as ‘drugs with associations’.
Additional analysis on the risk of specific anomalies
with the respective drug class was carried out by compar-
ing the user rates in case mothers and mothers in the ref-
erence population. Increases in ORs were found for most of
the drug classes with specific anomalies, but failed to reach
statistical significance.
3.2 P-gp-Mediated Drug Interactions and the Risk
of Congenital Anomalies
The risk of congenital anomalies was found to be affected
by P-gp-mediated drug interactions (Fig. 2). For all P-gp
substrates, including drugs without associations, we could
not show an effect of the combination with any inhibitor or
inducer on the risk for overall anomalies compared with the
use of the substrate alone (OR 0.81, 95 % CI 0.52–1.27,
p = 0.4). However, the risk for specific anomalies was
significantly increased to nearly threefold in mothers using
any of the 13 drugs with associations in combination with
other substrates (OR 4.17, 95 % CI 1.75–9.91, p = 0.003).
The risk was further augmented up to sixfold with the
addition of inhibitors (OR 13.03, 95 % CI 3.37–50.42,
p = 0.003). The risk estimations for individual drugs with
associations are available in electronic supplementary
Table 2.
The same pattern of risk increment was observed when
analyses were conducted separately for substrates and
substrate/inhibitor groups within the drugs with asso-
ciations. For substrates (cimetidine, ranitidine, risperidone,
citalopram), herein referred to as ‘drug’, the use of ‘drug ?
substrate(s)’ significantly increased the risk of specific
anomalies compared with its use alone (OR 7.64, 95 % CI
1.61–36.33, p = 0.023). The combination of ‘drug ?
substrate(s) ? inhibitor(s)’ showed a slight increase in risk
but failed to reach statistical significance, probably because
of the low number of exposed cases. For substrates/in-
hibitors (omeprazole, pantoprazole, haloperidol, quetiap-
ine, fluoxetine, paroxetine, sertraline, fluvoxamine), the
combination of ‘drug ? substrate(s)’ significantly in-
creased the risk of specific anomalies by approximately
threefold (OR 3.21, 95 % CI 1.12–9.23, p = 0.04). The
Fig. 1 User rates (in case mothers) and prescription rates (in mothers of the reference population) of drugs associated with P-gp transport. One
mother may be counted more than once. The list of all drugs associated with P-gp transport is available in Table 1 of the electronic
supplementary material. The classifications of drugs according to P-gp substrate specificity and drugs with at least one user in both cases and
reference population are as follows: P-gp substrate (cimetidine, ranitidine, domperidone, propranolol, betamethasone, hydrocortisone,
triamcinolone, doxycycline, tetracycline, sumatriptan, lamotrigine, levetiracetam, risperidone, clomipramine, nortriptyline, citalopram,
venlafaxine, fexofenadine); P-gp substrate/inhibitor (omeprazole, pantoprazole, simvastatin, atorvastatin, clarithromycin, azithromycin,
ketoconazole, itraconazole, cyclosporine, haloperidol, quetiapine, amitriptyline, fluoxetine, paroxetine, sertraline, fluvoxamine, terfenadine);
P-gp substrate/inducer (dexamethasone, morphine, phenytoin, carbamazepine); P-gp inhibitor (progesterone, duloxetine, mefloquine); P-gp
inducer (insulin); P-gp inhibitor/inducer (bromocriptine, midazolam); P-gp substrate/ inhibitor/inducer (erythromycin, diltiazem). P-gp
P-glycoprotein
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addition of inhibitor(s) further increased the risk up to
tenfold, but with a large confidence interval (OR 13.33,
95 % CI 2.58–68.96, p = 0.017).
Morphine was the only substrate/inducer used in both
cases and the reference population—one user among cases
and three users in the reference population. These numbers
impede further analysis of drug interactions for morphine.
However, this drug was included in the analysis where all
drugs with associations were combined.
4 Discussion
Our study was the first to describe the pattern of use of
drugs associated with P-gp transport in the first trimester of
pregnancy. We also found that P-gp-mediated drug inter-
actions have an effect on the risk of congenital anomalies,
as a proxy for fetal exposure. It has already been shown
that these interactions affect drug pharmacokinetics and the
pharmacodynamic effects of multiple drugs, mostly based
Fig. 2 The risk estimation of overall and specific anomalies with several patterns of P-gp-mediated drug interactions. The reference for the odds
ratio calculation is the use of drug substrates alone for each subgroup. a Showed no increased risk of overall anomalies associated with drug
interactions in 41 P-gp substrates, p = 0.4 (see Fig. 1 for the list of drugs); b, c showed the risk changes for specific anomalies (heart, genital,
respiratory, musculoskeletal and nervous system) in 13 drugs previously associated with these anomalies (cimetidine, ranitidine, omeprazole,
pantoprazole, morphine, haloperidol, risperidone, quetiapine, citalopram, fluoxetine, paroxetine, sertraline, fluvoxamine), both with p = 0.003;
d, e showed the risk changes for specific anomalies (heart, musculoskeletal and nervous system) in P-gp substrates previously associated with
these anomalies (cimetidine, ranitidine, risperidone, citalopram), p = 0.023 and 0.16, respectively; f, g showed the risk changes for specific
anomalies (genital, musculoskeletal and nervous system) in P-gp substrates/inhibitors previously associated with these anomalies (omeprazole,
pantoprazole, haloperidol, quetiapine, fluoxetine, paroxetine, sertraline, fluvoxamine), p = 0.04 and 0.017, respectively. assoc. associations, CI
confidence interval, M-H Mantel–Haenszel, P-gp P-glycoprotein, S substrates, S/I substrates/inhibitors. Asterisk indicates p\ 0.05 (Fisher’s
exact test)
Table 2 Number of users of drug/drug classes associated with specific congenital anomalies, and the risk determination of these anomalies from


















[N = 4634 - ns]
H2-receptor antagonist
(cimetidine, ranitidine)
Heart (ns = 244) 5 (0.4) 3 (0.1) 0.037






9 (2. 2) 52 (1.2) 0.046 327 (1.3) 1.72 (0.88–3.36) 0.11
Morphine Respiratory
(ns = 84)












11 (3.2) 74 (1.7) 0.054b 576 (2.3) 1.4 (0.76–2.56) 0.28
CI confidence interval, ns number of cases of respective type of anomalies, OR odds ratio, SSRIs selective serotonin reuptake inhibitors
a Fisher’s exact test
b Although not significant, SSRIs will be included in further analysis due to previous warnings of teratogenicity
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on the interactions occurring in the small intestine, liver
and kidney (see review by Akamine et al. [16]). Since P-gp
is also substantially expressed in the placenta, the P-gp
inhibition and induction is expected to play a role in de-
termining fetal drug exposure. P-gp inhibition is expected
to lead to a higher amount of drugs transferred into the fetal
circulation, which can potentially harm the fetus. The
pattern of risk increment between ‘drug ? substrate(s)’ and
‘drug ? substrate(s) ? inhibitor(s)’ was the same for P-gp
substrates and substrates/inhibitors, although we found a
large CI due to a limited number of exposed mothers.
Several preclinical studies have demonstrated the role of
P-gp inhibition in the drug transport mechanism in the
placenta, using placental samples after delivery (ap-
proximately 37–42 weeks of gestation). In studies using the
dually perfused human placental model, the maternal-to-
fetal transport of saquinavir, indinavir and lopinavir was
shown to increase with P-gp inhibition [17, 18]. The
transfer of paclitaxel, methadone and talinolol were also
affected by the drug interactions mediated by P-gp [19–21].
In order to evaluate the role of P-gp-mediated drug inter-
actions in the risk of congenital anomalies, it is important
that the P-gp level in preclinical studies is comparable to
that observed in the early stages of pregnancy. As the ex-
pression level of P-gp is known to decrease when preg-
nancy advances [22, 23], it may be expected that the results
of these preclinical studies may not fully demonstrate the
degree of P-gp inhibition and the effect on fetal drug ex-
posure in the first trimester of pregnancy. The placental
expression of P-gp itself is also subject to interindividual
variation, in which the expression level may differ among
mothers [19]. However, the correlation between expression
level and activity of the placental P-gp also remains un-
clear, leading to the need for different methods in order to
evaluate the net effect of placental drug transfer [19].
Apart from P-gp transport, there are other factors that
may contribute to the net concentration of a drug in the
placenta. These factors include changes in placental per-
meability which may readily alter maternal-to-fetal drug
disposition [24]. Increased permeability of the placenta is
caused by a reduction in placental thickness, as well as
increased surface area and placental blood flow. Another
factor is the drug interactions mediated by the metabolic
enzymes, the cytochrome (CYP) 450. P-gp and CYP450
enzymes were shown to share a broad substrate specificity
[16, 25]. In this study, we assume that, at least from 2002,
the clinically significant CYP-mediated drug interactions
had already been avoided during prescribing and dispens-
ing by the software-supported medications surveillance
commonly used in The Netherlands [26]. Furthermore, the
metabolic enzymes expressed in the placenta seemed to
add minor contributions to fetal drug transfer [10]. The last
factor was the genetic variability of the genes encoding for
P-gp and CYP450 relevant to the pharmacokinetics of each
drug investigated. Genotype-dependent drug interactions
can also cause variations in the drug’s efficacy and toxicity
profile [27, 28].
Since this study aims to explore the role of P-gp in fetal
drug exposure using a technical approach, the list of drugs
tested in this study was based on in vivo and in vitro studies
with regard to their substrate specificity to P-gp transport.
A drug identified in an in vitro study is not necessarily of
clinical importance, and extrapolating from animal evi-
dence to humans is not always simple. To improve the
quality of results in future studies, it is suggested to focus
on specific drug classes with documented clinical evidence
on P-gp transport activity.
Although the proportion of drug transferred across the
placenta is considered minimal, any change in the placental
barrier mechanism may cause significant changes in fetal
drug concentration. These changes can be detrimental to
the fetus, especially if the drugs have a small therapeutic
index, are teratogenic, or can potentially affect the normal
physiological transport of nutrients to the fetus [29].
4.1 Strengths and Limitations
Our study was the first to report on the occurrence of P-gp-
mediated drug interactions in pregnant women and the
effect on the fetus. Drug use and the period of use are well-
documented in both databases used in this study, and the
cases and population sampling were carried out in the same
time period. Moreover, the prescription records in the
IADB.nl are virtually complete due to the high patient–
pharmacy commitment in The Netherlands [12].
In the determination of the ‘drugs with associations’, we
did not find the previously reported associations between
drug or drug groups with specific types of anomalies, for
example antiepileptics and neural tube defects [30]. There
are several reasons for this. First, our study was not set up
to find these associations because we focused on P-gp-
mediated drug interactions and therefore we used the user
rates from cases with all other anomalies within our case
group as a reference group. It is a convenient method to
quickly identify potentially harmful drugs and then con-
tinue with the next analysis to identify whether drug in-
teractions may change the risk. In contrast, in most
pharmacovigilance studies, the aim is to find a signal of
teratogenicity of a drug, and the major malformation rates
are usually calculated by using total birth as a denominator.
Second, our study might be underpowered to detect pre-
viously reported associations.
One of our limitations was selection bias in the refer-
ence population since only children who had received
prescription drugs were registered in the IADB.nl. In the
IADB.nl, only 65 % of children in the population could be
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linked to their mother. The most important reasons for
missing the linkage were that the mother had a separate
address registration number, the mother was registered
with another pharmacy in the town, or the mother did not
live at the same address [13]. We do not have information
on the non-linked children; however, since linkage is based
on birth date and address rather than health profiles, the
linkage may have been random and is unlikely to have
substantially influenced exposure and outcome. Although
the Pregnancy IADB can only link a child to a mother if
they had taken prescription drugs, it is well-known that
approximately 80 % of children, before the age of 2 years,
have been prescribed at least one medication that was
dispensed from the pharmacy [31]. We therefore assumed
that the reference population was comparable to the un-
selected group.
There was also a potential classification bias in the expo-
sure period of drugs in the reference population as the gesta-
tional period of the pregnancies in the reference population
was based on estimation (assumption of 293 days of gesta-
tion). Furthermore, exposure definition differs between cases
and the reference population, which is based on actual use and
prescriptions, respectively. Actual exposure in the reference
population is expected to be lower than observed, which may
have led to an underestimation of the observed increased risk.
IADB.nl only registered the live births, therefore we cannot
include stillborn children and pregnancies that underwent
miscarriage or termination. There is a possibility that the risk
estimations for congenital anomalies in the results are over-
estimated if the exposure rate in these children/pregnancies
are higher comparedwith live-born children. However, due to
a low rate of stillbirths, miscarriages and terminations of
pregnancy in the population-based statistics (0.2–0.4 % for
stillbirths [32]), we expect the change to be very minimal. A
similar assumption applies to children in the Pregnancy IADB
who might also have congenital anomalies. The rate of con-
genital anomalies is approximately 3 % of the total number of
births, therefore these numbers are not expected to cause
significant changes in risk estimation [33].
Confounding by indication was also assumed to have
minor implications on the results. This type of confounding
refers to those situations in which the indication for treat-
ment acts as a confounder, in this case the disease influ-
ences the exposure to P-gp substrates and acts as a risk
factor for congenital anomalies. In this study, the exposure
variable consists of a broad range of drugs, each with
specific indications. One of the known risk factors for
congenital anomalies is maternal diabetes mellitus [34],
and insulin is one of the drugs associated with P-gp
transport; however, insulin is an inducer to this transporter,
not a substrate, therefore it is not included in the analysis
for the effect of P-gp inhibition on the risk of congenital
anomalies.
There are also other confounding factors that we were
not able to address, such as maternal smoking behavior,
alcohol consumption and other risk factors for congenital
anomalies. Therefore, our results warrant further epi-
demiological studies, preferably with a higher number of
exposed cases and focusing on exposure to selected ter-
atogenic drugs in specific congenital anomalies in combi-
nation with potent inhibitors or inducers.
5 Conclusions
The use of drugs associated with P-gp transport was
common in pregnancy, and some mothers had to use more
than one of these drugs. For several drug classes that were
associated with specific anomalies, P-gp-mediated drug
interactions were found to increase the risk for those
anomalies. Apart from other factors that may affect fetal
drug exposure, for these drug classes, P-gp plays a
clinically relevant role in limiting drug exposure, as pre-
viously suggested in preclinical studies. The absolute risk
of such interactions may be modest, but at the P-gp level it
showed a significant increment in the risk of congenital
anomalies in drugs suspected to be teratogenic. Moreover,
this knowledge may assist drug individualization in preg-
nancy, especially in chronic diseases.
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